Voyager Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $95.1M | $117.4M |
| FY2022 | — | $59.0M | $99.0M |
| FY2023 | — | $236.3M | $68.8M |
| FY2024 | — | $299.8M | $71.4M |
| FY2025 | — | $196.1M | $65.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $95.1M | $117.4M |
| FY2022 | — | $59.0M | $99.0M |
| FY2023 | — | $236.3M | $68.8M |
| FY2024 | — | $299.8M | $71.4M |
| FY2025 | — | $196.1M | $65.3M |